Suppr超能文献

抗CD3单克隆抗体加白细胞介素2诱导的人CD4+辅助/杀伤性T细胞的双特异性抗体导向抗肿瘤活性

Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.

作者信息

Nishimura T, Nakamura Y, Takeuchi Y, Gao X H, Tokuda Y, Okumura K, Habu S

机构信息

Department of Immunology, Tokai University School of Medicine, Isehara.

出版信息

Jpn J Cancer Res. 1991 Nov;82(11):1207-10. doi: 10.1111/j.1349-7006.1991.tb01782.x.

DOI:10.1111/j.1349-7006.1991.tb01782.x
PMID:1836455
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5918327/
Abstract

Freshly isolated human CD4+ T cells can not respond to recombinant interleukin 2 (rIL-2) because of their lack of p75 IL-2 receptor expression. However, we succeeded in inducing a marked proliferation of purified CD4+ T cells by activation with rIL-2 plus anti-CD3 monoclonal antibody (mAb) cross-linked to a plastic plate. The proliferated CD4+ T cells produced a significant amount of IL-2 upon stimulation with phorbol ester plus A23187. Interestingly, CD4+ T cells activated with anti-CD3 mAb plus rIL-2 revealed a strong cytotoxic activity against Fc receptor (FcR)-positive tumor cells in the presence of anti-CD3 mAb. Moreover, the CD4+ T cells could lyse FcR-negative glioma cells by targeting with bispecific mAb containing anti-CD3 mAb and anti-glioma mAb. Thus, we demonstrated that rIL-2 and immobilized anti-CD3 mAb allowed the rapid generation of human CD4+ helper/killer T cells, which may be useful for the development of a new adoptive tumor immunotherapy.

摘要

新鲜分离的人CD4+ T细胞由于缺乏p75白细胞介素2（IL-2）受体表达，无法对重组白细胞介素2（rIL-2）作出反应。然而，我们通过用rIL-2加交联到塑料板上的抗CD3单克隆抗体（mAb）激活，成功诱导了纯化的CD4+ T细胞显著增殖。增殖的CD4+ T细胞在用佛波酯加A23187刺激后产生了大量的IL-2。有趣的是，在用抗CD3 mAb加rIL-2激活的CD4+ T细胞在抗CD3 mAb存在的情况下，对Fc受体（FcR）阳性肿瘤细胞显示出强大的细胞毒性活性。此外，CD4+ T细胞可以通过用含有抗CD3 mAb和抗胶质瘤mAb的双特异性mAb靶向裂解FcR阴性胶质瘤细胞。因此，我们证明rIL-2和固定化抗CD3 mAb能够快速产生人CD4+辅助/杀伤性T细胞，这可能对开发新的过继性肿瘤免疫疗法有用。

相似文献

1
Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.抗CD3单克隆抗体加白细胞介素2诱导的人CD4+辅助/杀伤性T细胞的双特异性抗体导向抗肿瘤活性
Jpn J Cancer Res. 1991 Nov;82(11):1207-10. doi: 10.1111/j.1349-7006.1991.tb01782.x.
2
Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.抗CD3单克隆抗体加重组白细胞介素-2诱导的人CD4+辅助/杀伤性T细胞的产生、增殖及靶向作用。一种过继性肿瘤免疫治疗的有效策略。
J Immunol. 1992 Jan 1;148(1):285-91.
3
Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells.用交联抗CD3单克隆抗体OKT3刺激纯化的人T细胞：重组白细胞介素-1是CD4+CD29+CD45RA- T细胞的共刺激因子。
Scand J Immunol. 1990 Oct;32(4):359-71. doi: 10.1111/j.1365-3083.1990.tb02930.x.
4
Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy.人c-erbB-2原癌基因产物作为双特异性抗体导向的过继性肿瘤免疫疗法的靶点。
Int J Cancer. 1992 Mar 12;50(5):800-4. doi: 10.1002/ijc.2910500523.
5
Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1.超抗原加主要组织相容性复合体II类分子或CD3单克隆抗体对T细胞刺激的分析：纯化的黏附配体VCAM-1、ICAM-1而非ELAM-1的共刺激作用
J Exp Med. 1991 Oct 1;174(4):901-13. doi: 10.1084/jem.174.4.901.
6
Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.用于过继性肿瘤免疫治疗的人CD4 +辅助/杀伤性T细胞大规模培养系统。
Br J Cancer. 1992 Jul;66(1):20-6. doi: 10.1038/bjc.1992.210.
7
Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.用重组白细胞介素2和抗CD3抗体刺激的人胶质瘤浸润淋巴细胞的细胞学特征
Jpn J Cancer Res. 1991 Mar;82(3):339-45. doi: 10.1111/j.1349-7006.1991.tb01851.x.
8
Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.固定化抗CD3单克隆抗体诱导同种反应性细胞溶解T淋巴细胞。人细胞溶解T淋巴细胞分化需求分析。
Immunology. 1990 Jul;70(3):357-64.
9
The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens.抗T细胞单克隆抗体9.3（抗CD28）可提供辅助信号，在使用固定化抗CD3和丝裂原激活T细胞时，无需辅助细胞参与。
Cell Immunol. 1989 Apr 15;120(1):205-17. doi: 10.1016/0008-8749(89)90188-3.
10
Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.通过克隆性分布的功能性表面分子表达鉴定人类CD3-CD16+自然杀伤（NK）细胞的四个亚群：NK克隆的亚群分配与介导特异性同种异体抗原识别能力之间的相关性。
J Exp Med. 1990 Dec 1;172(6):1589-98. doi: 10.1084/jem.172.6.1589.

引用本文的文献

1
Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.利用双特异性抗体武装的激活 T 细胞靶向和杀伤脑胶质瘤。
BMC Cancer. 2013 Feb 22;13:83. doi: 10.1186/1471-2407-13-83.
2
Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.OK-432在小鼠肿瘤部位诱导抗肿瘤L3T4阳性T细胞
Cancer Immunol Immunother. 1993;36(4):245-50. doi: 10.1007/BF01740906.
3
Activated CD4+ T cells preferentially take up lipid microspheres, but resting cells do not.活化的CD4 + T细胞优先摄取脂质微球，但静息细胞则不然。
Clin Exp Immunol. 1995 Mar;99(3):479-85. doi: 10.1111/j.1365-2249.1995.tb05576.x.
4
Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.用于过继性肿瘤免疫治疗的人CD4 +辅助/杀伤性T细胞大规模培养系统。
Br J Cancer. 1992 Jul;66(1):20-6. doi: 10.1038/bjc.1992.210.

本文引用的文献

1
Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+.对HLA - DR6抗原具有同种特异性的长期人类细胞溶解T细胞系为OKT4阳性。
Proc Natl Acad Sci U S A. 1982 Apr;79(7):2365-9. doi: 10.1073/pnas.79.7.2365.
2
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.通过体内给予纯化的白细胞介素2增强长期培养的T淋巴细胞的抗肿瘤治疗效果。
J Exp Med. 1982 Apr 1;155(4):968-80. doi: 10.1084/jem.155.4.968.
3
Surface markers of cloned human T cells with various cytolytic activities.具有不同细胞溶解活性的克隆化人T细胞的表面标志物。
J Exp Med. 1981 Aug 1;154(2):569-74. doi: 10.1084/jem.154.2.569.
4
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.环磷酰胺辅助的已建立肿瘤的过继性免疫疗法取决于肿瘤诱导的抑制性T细胞的清除。
J Exp Med. 1982 Apr 1;155(4):1063-74. doi: 10.1084/jem.155.4.1063.
5
Differential requirements for activation and growth of unprimed cytotoxic and helper T lymphocytes.未致敏细胞毒性T淋巴细胞和辅助性T淋巴细胞激活与生长的不同需求。
Eur J Immunol. 1983 Sep;13(9):719-25. doi: 10.1002/eji.1830130906.
6
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.淋巴因子激活的杀伤细胞现象。白细胞介素2激活的自体人外周血淋巴细胞对天然杀伤抗性新鲜实体瘤细胞的杀伤作用。
J Exp Med. 1982 Jun 1;155(6):1823-41. doi: 10.1084/jem.155.6.1823.
7
Distinction between antigen receptor and IL 2 receptor triggering events in the activation of alloreactive T cell clones with calcium ionophore and phorbol ester.用钙离子载体和佛波酯激活同种异体反应性T细胞克隆时，抗原受体与白细胞介素-2受体触发事件之间的区别。
J Immunol. 1985 Jun;134(6):3649-55.
8
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.对转移性癌症患者进行自体淋巴因子激活的杀伤细胞和重组白细胞介素-2全身给药的观察。
N Engl J Med. 1985 Dec 5;313(23):1485-92. doi: 10.1056/NEJM198512053132327.
9
Use of Millipore diffusion chambers to assay in vivo IL-2 activity.使用密理博扩散小室测定体内白细胞介素-2活性。
J Immunol Methods. 1985 Apr 22;78(2):239-45. doi: 10.1016/0022-1759(85)90081-x.
10
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.纯化的人白细胞介素2的体内给药。I. 源自Jurkat细胞系的白细胞介素2的半衰期和免疫学效应。
J Immunol. 1985 Jan;134(1):157-66.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验